Abstract: The present invention relates to novel compositions containing a mixture of two or three bioflavonols like isoquercetin, quercetin-4′-glycoside, rutin and quercetin, which show differences in their pharmacokinetics. These compositions are useful as food supplements possessing preventive properties against damage to human tissues due to their antioxidant properties. Furthermore, these compositions secure a continuum of the presence of bioflavonols having the same aglycone in human plasma over an extended period of time.

Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. where R3 is —CH2NH2, —CH2CH2NH2, or —CH2NHC(O)OC(CH3)3.

Abstract: This invention relates to a composition containing the three active ingredients: a) one or more phosphatidyl serines, b) one or more methyl transporters, and c) one or more compounds selected from methyl and methylene donors.

Abstract: The instant invention is concerned with aryl and heteroaryl acetic acid and oxyacetic acid compounds, which are useful as antidiabetic compounds. Compositions and methods for their use in the treatment of diabetes and related diseases and for lowering triglyceride levels are disclosed.

Abstract: The invention relates to TN and STN displays having very short switching times and good steepness and angular dependence and to the novel nematic liquid crystal mixtures employed therein, which are distinguished by comprising at least one compound of formula IA, where R3 is an alkenyl group having from 2 to 7 C atoms, and comprising at least one compound of formula IB, where R1 and R2 each, independently of one another, are an alkyl, alkoxy or alkenyl group having from 1 to 12 C atoms, with the additional option of 1 or 2 non-adjacent CH2 groups being replaced by —O—, —CH═CH—, —CO—, —OCO— or —COO— in such a way that O atoms are not linked directly to one another, and L is H or F.

Abstract: The invention relates to a process for the preparation of ortho-alkylated benzoic acid derivatives of the formula I characterized in that an aryl bromide of the formula II is reacted with a secondary or tertiary organolithium compound and CO2.

Abstract: Polymerizable tolanes of formula I wherein P, Sp, X, n, A1, A2, Z1, Z2, m1, m2, L1, L2, r and R have the meanings defined herein, polymerizable liquid crystal compositions comprising at least one compound of formula I, linear or crosslinked liquid crystal polymers obtainable from these compounds and compositions, are suitable for use in optical elements such as polarizers, retardation and compensation films, alignment layers, color filters or holographic elements. They are also suitable for use in liquid crystal displays such as PDLC, polymer gel or polymer stabilized cholesteric texture (PSCT) displays, as well as for use in adhesives, synthetic resins with anisotropic mechanical properties, cosmetics, diagnostics or liquid crystal pigments, for decorative and security applications, and for nonlinear optics or optical information storage.

Abstract: The present invention relates to an orally administrable galenic formulation allowing improved absorption by the transmembrane or paracellular route in the gastrointestinal tract of active ingredients which are hydrophilic or ionizable in physiological media. The galenic formulation comprises at least one active ingredient, an absorption-promoting agent, and one or more pharmaceutically acceptable excipients.

Abstract: The present invention provides assays in which intracellular chelators are used to alter the kinetics of signal generation triggered by divalent cations, particularly calcium influx into the cell. The use of an intracellular chelator in the assay can delay and prolong the signal, allowing the signal to be detected by automated instrumentation without the need for simultaneous liquid handling at the time of detection.

Abstract: A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.

Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I in which R1 is an alkoxy group having up to 12 carbon atoms.

Abstract: The invention relates to a method for symmetrically disubstituting carboxylic acid amides on the geminal carbonyl-C-atom using grignard reagents in the presence of a metal alcoholate compound used as a catalyst and in the presence of another organometalic compound used as a co-catalyst.

Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein Ts is a tosylate group and R is an alkyl group, an unsubstituted phenyl or substituted phenyl ring, or a benzyl or substituted benzyl group; which comprises: (i) cyclising a compound of formula (II) in the presence of a suitable catalyst; and (ii) purifying and collecting the resultant compound of formula (I).

Abstract: The invention concerns hydrogenated phenanthrenes of formula I wherein the parameters have the meanings given in the text and their use in liquid crystal compositions.

Abstract: A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

Abstract: The invention relates to new thienothiophene derivatives, their use as semiconductors or charge transport materials, in optical, electrooptical or electronic devices like for example organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the thienothiophene derivatives.

Abstract: The present invention relates to novel compositions containing a mixture of two or three bioflavonols like isoquercetin, quercetin-4′-glycoside, rutin and quercetin, which show differences in their pharmacokinetics. These compositions are useful as food supplements possessing preventive properties against damage to human tissues due to their antioxidant properties. Furthermore, these compositions secure a continuum of the presence of bioflavonols having the same aglycone in human plasma over an extended period of time.

Abstract: The invention relates to a method for asymmetrically disubstituting carboxylic acid amides on the geminal carbonyl-C-atom using two grignard reagents in the presence of a metal alcoholate compound used as a catalyst and in the presence of another organometalic compound used as a co-catalyst.

Abstract: The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to chiral compounds of formula I wherein R1, R2, MG1, MG2, Sp, X, Y, a, b, c and d have the meaning given in claim 1, to a liquid crystalline mixture comprising at least one chiral compound of formula I, to a polymerizable liquid crystalline mixture comprising at least one chiral compound of formula I and optionally at least one polymerizable mesogenic compound, to the use of such a liquid crystalline mixture or a polymerizable liquid crystalline mixture for the preparation of anisotropic polymer films with a chiral liquid crystalline phase, for active and passive optical elements like polarizers, compensators or color filters and for liquid crystal displays, for example STN, TN, AMD-TN, temperature compensation, guest-host or phase change displays, or surface stabilized or polymer stabilized cholesteric texture (SSCT, PSCT) displays, to cholesteric liquid crystal displays comprising liquid crystalline mixtures comprising chiral compounds of formula I and to polymer fil